Bblueprint
Absci combines generative AI and wet-lab data to create antibody medicines
Understand Absci’s antibody design platform, ABS-201 clinical program and partnership routes, with clear distinctions between predictions and evidence.
Models & infrastructureSat, 3 Oct 2026
8 minread


